Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Breaking News
Crash closes part of NC 55 at Triangle Expressway toll road near Morrisville
Program
On WRAL Monday at 6: Known carcinogens hiding in your childâs classroom? WRAL Investigates why some local schools are refusing to take action
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Exelixis Inc
(NQ:
EXEL
)
25.81
-0.07 (-0.27%)
Streaming Delayed Price
Updated: 2:20 PM EDT, Aug 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
523,101
Open
25.87
Bid (Size)
25.80 (2)
Ask (Size)
25.81 (3)
Prev. Close
25.88
Today's Range
25.68 - 25.94
52wk Range
18.64 - 27.53
Shares Outstanding
315,048,788
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
3 Stocks to Buy for a Soft Landing, If There Is One
August 15, 2024
Recent economic data is reigniting talk about a soft landing for the economy; here are three stocks to consider if a soft landing materializes
Via
MarketBeat
Topics
Economy
Exposures
Economy
Interest Rates
NASDAQ:EXEL, an undervalued stock with good fundamentals.
August 15, 2024
Don't overlook EXELIXIS INC (NASDAQ:EXEL)—it's a hidden gem with strong fundamentals and an attractive price tag.
Via
Chartmill
Performance
YTD
+7.86%
+7.86%
1 Month
+10.35%
+10.35%
3 Month
+26.89%
+26.89%
6 Month
+17.53%
+17.53%
1 Year
+16.37%
+16.37%
More News
Read More
Stock Market Rally Begins After Global Rout; Palantir, Eli Lilly, Fortinet Jump: Weekly Review
August 09, 2024
Via
Investor's Business Daily
Expert Outlook: Exelixis Through The Eyes Of 5 Analysts
August 08, 2024
Via
Benzinga
Analyst Sees Exelixis At Inflection Point Despite Mixed Trial Results
August 07, 2024
Via
Benzinga
Exposures
Product Safety
US Stocks Set To Extend Gains Despite Mixed Earnings, VIX Dips Back Toward Pre-Sell-Off Levels: Analyst Says Pullback Is A 'Growth Scare' And Not 'Calamity'
August 07, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Exelixis (EXEL) Q2 2024 Earnings Call Transcript
August 07, 2024
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
EXEL Stock Earnings: Exelixis Beats EPS, Beats Revenue for Q2 2024
August 06, 2024
Via
InvestorPlace
Exelixis Announces Second Quarter 2024 Financial Results and Provides Corporate Update
August 06, 2024
From
Exelixis, Inc.
Via
Business Wire
Wall Street Rebounds After Selloff, VIX Falls, Dollar Surges Against Yen: What's Driving Markets Tuesday?
August 06, 2024
Via
Benzinga
Topics
Economy
Stocks
Exposures
Economy
US Equities
Exelixis Announces U.S. Food and Drug Administration (FDA) Accepted the Supplemental New Drug Application for Cabozantinib for Patients with Advanced Neuroendocrine Tumors
August 06, 2024
From
Exelixis, Inc.
Via
Business Wire
US Stocks Set To Open Higher After Monday's Crash, VIX Plummets: Analyst Says Would Have Worried If Market Surged Higher Without Correction
August 06, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Exelixis to Release Second Quarter 2024 Financial Results on Tuesday, August 6, 2024
July 23, 2024
From
Exelixis, Inc.
Via
Business Wire
In a market where value is scarce, NASDAQ:EXEL offers a refreshing opportunity with its solid fundamentals.
July 18, 2024
Via
Chartmill
7 Cheap Biotech Stocks With Major Upside Potential
July 09, 2024
Via
InvestorPlace
When you look at NASDAQ:EXEL, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
June 27, 2024
Via
Chartmill
Don't overlook NASDAQ:EXEL—it's a hidden gem with strong fundamentals and an attractive price tag.
June 06, 2024
Via
Chartmill
10 Health Care Stocks Whale Activity In Today's Session
May 31, 2024
Via
Benzinga
Over $8M Bet On This Health Care Stock? Check Out These 4 Stocks Insiders Are Buying
May 31, 2024
Via
Benzinga
Exelixis to Present at the William Blair 44th Annual Growth Stock Conference
May 28, 2024
From
Exelixis, Inc.
Via
Business Wire
Exelixis Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Cipla Limited and Cipla USA
May 20, 2024
From
Exelixis, Inc.
Via
Business Wire
In a market where value is scarce, NASDAQ:EXEL offers a refreshing opportunity with its solid fundamentals.
May 15, 2024
Via
Chartmill
Billionaire Jim Simons Owns These 2 Healthcare Stocks: Should You?
May 12, 2024
Via
The Motley Fool
MacroGenics Gets Downgraded Following Disappointing Prostate Cancer Trial Results: 'We Were Surprised By Reported Deaths'
May 10, 2024
Via
Benzinga
Just Say No to Drugs: 3 Pharma Stocks to Avoid
May 08, 2024
Via
InvestorPlace
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.